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Abstract
This study describes the successful synthesis of nitric oxide (NO)-releasing compounds
with biodegradable and injectable properties and demonstrates that the kinetics of NO
release vary according to the type of NO donor. The antimicrobial activity of NO-releasing
compounds against three common periodontal pathogens, i.e., Aggregatibacter actinomy-
cetemcomitans, Porphyromonas gingivalis, and Actinomyces israelii, was investigated
using a susceptibility assay. Human gingival fibroblasts were treated with NO-releasing
compounds at the minimum concentrations required for bacterial growth and cytotoxicity
was evaluated using the MTT cell proliferation assay. Our results suggest that NO-releasing
compounds can be used topically to treat both gram-negative and gram-positive periodontal
pathogens. Comparison of the antimicrobial activity and cytotoxicity assay results between
the NO-releasing compounds revealed that an NO donor comprising a macromolecule with-
out surface charge, a lower instantaneous NO concentration, and an adequate supply of
NO were associated with a strong bactericidal effect and low cytotoxicity. NO-releasing
compounds with these properties may be suitable for treatment of periodontitis.
Introduction
Antibacterial agents can be administered systemically or topically for control of infection in
periodontal tissue. Systemic administration of antibiotics has been proven to be effective in
suppressing progression of periodontitis [1]. However, overuse of antibiotics can have sys-
temic side effects and promote development of antibiotic-resistant pathogens, so periodontitis
cannot be treated via the systemic route for extended periods [2]. Antibiotics delivered topi-
cally can reach the base of the periodontal pockets, which act as a natural drug reservoir and
allow antibacterial concentrations to be maintained for long enough to have an antimicrobial
effect [3].
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Biodegradable and injectable materials are suitable for topical delivery of antibiotics. Non-
biodegradable materials should be removed after the antibiotic is released and may cause irri-
tation and inflammation at the treated site. A biodegradable vehicle has the advantage of keep-
ing patient visits to a minimum. Injection by syringe is a simple procedure for delivery of
antibiotic agents and ensures compliance. The procedure requires standard and inexpensive
devices, and the antibiotic can be applied rapidly and easily without pain or discomfort to the
patient [4].
Nitric oxide (NO), a gaseous reactive free radical species produced in mammalian cells,
plays a crucial role in the immune response to pathogens [5] and is implicated in the angiogen-
esis that occurs at sites of inflammation. NO and reactive oxygen intermediates, such as NO
radicals, nitrogen dioxide, dinitrogen trioxide, and peroxynitrite, have bactericidal effects via
deamination of DNA, strand breakage, and peroxidation of lipids [6] and could potentially be
used as antimicrobial agents. In view of its broad-spectrum antibacterial activity and efficient
targeting of both free-floating bacteria and bacterial biofilms, exogenous NO holds promise as
an antibacterial agent in various medical fields.
Several types of NO donors, i.e., functional moieties or molecules that generate NO, have
been developed for exogenous delivery of NO [7]. Diazeniumdiolates containing the [N(O)
NO]- functional group are able to generate two molecules of NO from each moiety, so have
been widely used to construct NO delivery systems. These NO donors can be easily functiona-
lized onto any material containing secondary amine groups. NO-releasing compounds con-
taining diazeniumdiolates have now been synthesized using various scaffold molecules, and
their antimicrobial activity and cytotoxicity have been investigated. Interestingly, it was found
that a macromolecular-based NO delivery system had greater antibacterial activity than a
delivery system containing a small-molecule NO donor [8]. The antibacterial activity of NO-
releasing compounds against free-floating periodontal pathogens [9] and dental biofilm [10]
has been demonstrated. These compounds have also been confirmed to be safe when used in
the oral cavity [11]. In a previous study, we investigated the cytotoxic effects of NO-releasing
compounds synthesized by addition of diazeniumdiolate to a water-soluble Pluronic-branched
polyethyleneimine conjugate [12]. Pluronic copolymer is approved by the US Food and Drug
Administration (FDA) for use as a support scaffold and has no apparent cytotoxicity, so has
good biocompatibility. This tri-block copolymer is also a good substrate for injectable hydrogel
and is biodegradable [13].
In this study, we investigated the bactericidal effect of Pluronic F68-branched polyethyleni-
mine-NONOates (F68-BPEI-NO) on three periodontal pathogens, i.e., Aggregatibacter actino-
mycetemcomitans, Porphyromonas gingivalis, and Actinomyces israelii. Two small-molecule NO
donors, i.e., pyrrolidine-NONOates (Py-NO) and diethyltriamine-NONOates (DETA-NO),
which release NO at different rates, were used to evaluate the effect of different NO delivery sys-
tems. The cytotoxicity of the NO-releasing system was evaluated in human gingival fibroblasts
(HGF-1) to assess the possibility of its therapeutic use in oral disease.
Materials and methods
Synthesis of NO-releasing compounds
A Pluronic F68-branched polyethyleneimine conjugate (F68-BPEI), the precursor of the poly-
mer with an additional NONOate species (F68-BPEI-NONOates), was synthesized according
to a previously described method with some modifications [14]. First, 1.79 g of 4-nitrophenyl
chloroformate (pNPC), dissolved in 40 ml of dichloromethane (DCM), was added dropwise to
10 g of Pluronic F68 containing 50 ml of DCM to activate the Pluronic F68. After stirring over-
night, the pNPC-conjugated Pluronic F68 (pNPC-F68) was purified by precipitation with cold
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diethyl ether. Next, 2.84 g of F68-pNPC was dissolved in 23.2 ml of DCM to generate a conju-
gating branched polyethyleneimine (BPEI). Thereafter, 1.76 g of BPEI 1.8 k was dissolved in
40 ml of DCM with 6 ml of TEA and the mixture was stirred at 0˚C for 15 min. After stirring,
the F68-pNPC solution was added dropwise to the BPEI-containing solution. The resulting
solution was stirred overnight and then warmed to room temperature. After the reaction, the
product was purified by precipitation with cold diethyl ether. The remaining BPEI was rem-
oved by dialysis, after which the final product was freeze-dried for storage.
Py-NO, DETA-NO, and F68-BPEI-NO were synthesized from each precursor (pyrrolidine,
diethylenetriamine, and F68-BPEI, respectively) by addition of NONOates to the secondary
amine moieties. Pyrrolidine (1.64 ml) was mixed with acetonitrile (5 ml), ether (5 ml), and
30% sodium methoxide (NaOMe) solution (3.9 ml). Diethylenetriamine (0.52 ml) was mixed
with acetonitrile (15 ml) and NaOMe solution (0.9 ml). F68-BPEI dissolved in 20 ml of metha-
nol (MeOH) was mixed with 3 ml of tetrahydrofuran and 0.2 ml of 30% NaOMe solution.
Each precursor-containing solution was placed in a high-pressure NO reactor with argon
purging at several intervals. The reactor was immediately filled with NO gas at 90 psi and
maintained at this pressure for 3 days to functionalize the diazeniumdiolates. After flushing
with argon gas at 20 psi, Py-NO and DETA-NO were collected by filtration and washed in
cold diethyl ether. F68-BPEI-NO was obtained by precipitation with cold diethyl ether. After
collection of the products, each product was placed under vacuum to remove any remaining
solvent, and then sealed and stored at −20˚C.
Measurement of NO release
The amount of NO released was measured using a Sievers 280i Nitric Oxide Analyzer (GE
Healthcare, Boulder, CO, USA), which measures chemiluminescence. The NONOate-contain-
ing materials were added to Dulbecco’s phosphate-buffered saline, and the release profile was
obtained. The DETA-NO release profile was analyzed up to its detection limit (1 pmol). NO
release was evaluated by characterizing multiple NO parameters, including [NO]t (number of
moles of NO released per mg of the material), td (duration of NO above 1 pmol/s), [NO]m
(maximum instantaneous concentration of NO released), tm (time required to reach [NO]m),
and t1/2 (half-life of NO released). For the bactericidal and cytotoxicity assays, the NO com-
pounds were brought into contact with bacteria and cells, respectively, 10 min after they were
mixed with solution. The kinetics of NO release were recorded at 0 and 10 min after the initial
NO release response.
Bacterial strains and cultivation
Aggregatibacter actinomycetemcomitans (ATCC 43718), Porphyromonas gingivalis (ATCC
33277), and Actinomyces israelii (ATCC 12102) were purchased from the American Type Cul-
ture Collection (ATCC, Manassas, VA, USA). For verification of decontamination, P. gingiva-
lis was cultured in trypticase soy agar supplemented with 5% sheep blood, hemin (1 μg/ml),
and vitamin K (0.2 μg/ml), and A. actinomycetemcomitans and A. israelii were grown in brain
heart infusion (BHI) agar at 37˚C under anaerobic conditions (5% H2, 10% CO2, and 85% N2).
A single colony of each type of bacterium was then cultivated with the appropriate medium.
For the susceptibility assay, P. gingivalis was cultivated in BHI broth containing hemin (1 μg/
ml) and vitamin K (0.2 μg/ml) and A. actinomycetemcomitans and A. israelii were cultivated in
BHI broth at 37˚C under anaerobic conditions. The bacteria were then counted using a bacte-
ria counting chamber (Marienfeld, Lauda-Konigshofen, Germany) and the concentration of
each type of bacteria was adjusted to 1 × 107 cells/ml by addition of fresh medium.
Nitric oxide-releasing compounds for treatment of periodontal disease
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Antimicrobial assay of NO compounds
The antimicrobial activity of the NO-releasing compounds against periodontal pathogens was
evaluated using a susceptibility assay according to the methods of the Clinical and Laboratory
Standards Institute [15]. A minimum inhibitory concentration (MIC) assay was carried out
using a 96-well polystyrene plate (SPL Life Sciences, Gyeonggi, Korea). Next, 180-μl aliquots of
BHI broth containing hemin and vitamin K for P. gingivalis or BHI broth for A. actinomyce-
temcomitans and A. israelii were dispensed into the wells of the plate. A solution containing
Py-NO, DETA-NO, or FBN dissolved in sterilized, distilled H2O was added to the 12th column
of the 96-well plate and serially diluted 2-fold progressing to the second column using a multi-
channel micropipette. The first column of each well contained broth only and served as a nega-
tive control. Finally, 20-μl bacterial suspensions (containing 1 × 105 cells) were inoculated into
each well. The plates were then incubated at 37˚C for 36 h under anaerobic conditions. Bacte-
rial growth was measured by optical density at a wavelength of 660 nm using a microplate
reader (SpectraMax M2, Molecular Devices, Sunnyvale, CA, USA). A 96-well plate containing
medium with dilution of NO-releasing compounds and inoculation of periodontal pathogens
was incubated for evaluation of the minimum bactericidal concentration (MBC). A 50-μl ali-
quot of liquid from each well was inoculated and spread onto BHI agar for A. actinomycetem-
comitans and A. israelii or onto trypticase soy agar containing sheep blood, hemin, and
vitamin K for P. gingivalis. The plates were then incubated at 37˚C for 3 days (A. actinomyce-
temcomitans and A. israelii) or 5 days (P. gingivalis) under anaerobic atmospheric conditions.
The lowest concentration that revealed no visible bacterial growth after subculturing was taken
to be the MBC.
In vitro cytotoxicity
HGF-1 (ATCC #CRL-2014) cells were cultured in Dulbecco’s modified Eagle’s medium sup-
plemented with 10% fetal bovine serum and 1% penicillin/streptomycin and incubated at 37˚C
under humidified conditions in 5% CO2. The cells were seeded with medium (100 μl) in a
96-well plate (SPL Life Sciences) at a density of 1 × 104 cells/well and incubated at 37˚C for 24
h. Solutions (100 μl) of control medium and NO-releasing medium prepared in Dulbecco’s
modified Eagle’s medium by the same method as that used for the bactericidal assay were
added to the cells and incubated at 37˚C for 24 h. Next, 20 μl of a 5 mg/ml solution of MTT
was added to each well and incubated for 4 h in the dark; 100 μl of medium was then aspirated
carefully from each well and 100 μl of dimethyl sulfoxide was added to each well to dissolve the
formazan precipitate. Absorption was measured at a wavelength of 570 nm using a VERSAmax
tunable microplate reader (Molecular Devices). The viability of the cells in each well was calcu-
lated by comparing it with that of an untreated control (100%).
Statistical analysis
Differences between cell and bacterial samples treated or not treated with the NO-releasing
compounds were assessed for statistical significance using the Kruskal-Wallis test and the
Mann-Whitney U test, using SPSS version 23 software (IBM Corp., Armonk, NY, USA). A
p-value <0.05 was considered statistically significant.
Results
Kinetics of NO release
Release of NO from Py-NO, DETA-NO, and F68-BPEI-NO was characterized using chemilu-
minescence in Dulbecco’s phosphate-buffered saline at 37˚C. The number of moles of NO
Nitric oxide-releasing compounds for treatment of periodontal disease
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released per mg, duration of NO release, maximum instantaneous concentration of NO rel-
eased, time required to reach [NO]m, time required to reach the half-life of NO release, number
of moles of NO released per mg from 10 min to 24 h, and the instantaneous concentration of
NO released at 10 min were recorded for each compound (Table 1). Fig 1 shows the time course
of NO release and the cumulative NO release profiles after 10 min. Py-NO showed rapid NO
release with a high instantaneous NO concentration (49,227 pmol/mg/sec at 0 min, 1105.5
pmol/mg/sec at 10 min) for a short duration (1.5 h). In contrast, DETA-NO showed a slow NO
release with a relatively lower instantaneous concentration (546.3 pmol/mg/sec at 0 min, 213.8
pmol/mg/sec at 10 min) for a long duration (39.3 h). F68-BPEI-NONOates showed an intermit-
tent NO release speed with a much lower instantaneous NO concentration (114.7 pmol/mg/sec
at 0 min, 115.1 pmol/mg/sec at 10 min) and NO release was complete after 8.06 h. The calcu-
lated NO capacity from 1 mole of each molecule was evaluated from the NO release profile and
the molecular weight of each material (Py-NO, 1.48 mole NO/mol; DETA-NO, 0.609 mole
NO/mol; F68-BPEI-NO, 4.87 mole NO/1 mol).
Antimicrobial activity of NO-releasing compounds against periodontal
pathogens
F68-BPEI-NO, DETA-NO, F68-BPEI, and Py-NO inhibited growth of P. gingivalis at concen-
trations at or above 0.5 mM, 0.78 mM, 1 mM, and 12.5 mM, respectively. Lower MICs were
observed for each compound against A. israelii (0.5 mM, 0.78 mM, 1 mM, and 25 mM, for
F68-BPEI-NO, DETA-NO, F68-BPEI, and Py-NO, respectively). To inhibit the growth of A.
actinomycetemcomitans, the concentrations of NO-releasing compounds required were 0.39
mM for DETA-NO, 1.5 mM for F68-BPEI-NO, 1 mM for F68-BPEI, and 12.5 mM for Py-NO
(Fig 2). F68-BPEI-NO achieved greater inhibition of bacterial growth than its precursor,
F68-BPEI.
The MBC was also measured to analyze the bactericidal effect of the NO-releasing materials
in more detail. The MBC for F68-BPEI-NO, DETA-NO, and Py-NO was observed at 1 mM,
1.6 mM, and 25 mM, respectively, against P. gingivalis and 1 mM, 1.6 mM, and 25 mM against
A. israelii. Actinomycetemcomitans was more sensitive to DETA-NO, with the MBC of
DETA-NO, F68-BPEI-NO, and Py-NO being observed at 0.78 mM, 1 mM, and 25 mM,
respectively.
The bactericidal effects of Py and DETA were also investigated to confirm that the effects
were attributable to release of NO; both compounds inhibited the growth of periodontal
Table 1. NO release properties of tested materialsa.
[NO]t
b td
c [NO]m
d tm
e t1/2
f [NO]t,10p
g [NO]i,10p
h
Py-NO 9673 1.50 49227 2.2 3.25 119.9 1105.5
DETA-NO 3290 39.3 546.3 3.0 354 2802 213.8
F68-BPEI-NO 437 8.06 114.7 12.5 50.1 393.0 115.1
aMeasured in Dulbecco’s phosphate-buffered saline at 37˚C using a NOA 280i chemiluminescence NO analyzer.
b[NO]t, total number of nanomoles of NO released per mg (nmol/mg).
ctd, duration of NO release (h).
d[NO]m, maximum instantaneous concentration of NO released (pmol/mg/sec).
etm, time required to reach [NO]m (min).
ft1/2, half-life of NO release (min).
g[NO]t,10p, number of nanomoles of NO released per mg from 10 min to 24 h (nmol/mg).
h[NO]i,10p, instantaneous concentration of NO release (pmol/mg/sec). NO, nitric oxide
https://doi.org/10.1371/journal.pone.0199998.t001
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Fig 1. Characterization of NO-releasing compounds. “Time” indicates the time course after the bacteria or cells were exposed to NO. NO, nitric oxide.
https://doi.org/10.1371/journal.pone.0199998.g001
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pathogens at very high concentrations. Unlike Py-NO and DETA-NO, Py and DETA showed
antimicrobial activity at a concentration of 10-fold or more (S1 Fig).
Fig 2. Bactericidal efficacy of NO-releasing compounds.
https://doi.org/10.1371/journal.pone.0199998.g002
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Cytotoxicity to HGF-1 cells
The cytotoxicity of the NO-releasing compounds was investigated in HGF-1 cells by determi-
nation of the difference in metabolic activity between cells treated or not with the compounds
(Fig 3). When effective killing concentrations of the NO-releasing compounds were used
(2 mM, 1 mM, 25 mM, and 1.56 mM for F68-BPEI, F68-BPEI-NO, Py-NO, and DETA-NO,
respectively), their cytotoxicity values were 44.35%, 89.06%, 51.13%, and 70.80%, respectively.
Discussion
This study examined the potential suitability of NO-releasing compounds for use in clinical
practice as antibacterial agents against periodontal pathogens. Py and DETA are organic com-
pounds with monomolecular structures that are soluble to water and polar organic solvents
[16,17]. Although F68-BPEI is an organic compound with a macromolecular structure, it is
water-soluble and is biodegradable [18]. Moreover, when mixed with a solvent such as phos-
phate-buffered saline or distilled water, the physical state of F68-BPEI varies from a liquid at
low temperatures to a gel at body temperature [18]. Therefore, F68-BPEI may be a suitable
substrate for an injectable hydrogel and applied directly to treat patients with periodontitis
[14]. In contrast, Py and DETA can be used in an injectable form after being mixed with poly-
ethylene glycol ([19]. To evaluate the bactericidal efficiency of NO, bactericidal assays were
performed against A. actinomycetemcomitans (gram-negative), P. gingivalis (gram-negative),
and A. israelii (gram-positive). The cytotoxic effects of the NO-releasing compounds on HGF-
1 cells at the MBC were measured to evaluate the therapeutic potential of these agents.
Like in previous studies, the kinetics of NO release varied depending on the NO delivery
system used [20,21], although all NO-releasing compounds in this study used the same source
of NO (NONOates). Py and DETA are mono-molecules, but the NO-releasing compounds
Fig 3. Cytotoxic effects of NO-releasing compounds on HGF-1 cells. The bactericidal assay showed that the
minimum concentrations of NO-releasing compounds required to kill all pathogens within 24 h were 2, 1, 25, and 1.56
mM for F68-BPEI, F68-BPEI-NO, Py-NO, and DETA-NO, respectively. The cell viability in each group was calculated
by comparing the viability with that of an untreated control (100%). Asterisks indicate significant differences (P<0.05)
between groups.
https://doi.org/10.1371/journal.pone.0199998.g003
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derived from them release NO differently. Although Py-NO has a higher NO capacity com-
pared with the other compounds, the NO release kinetics are much more rapid than those of
other similar structures [22]. Therefore, Py-NO may exhibit low antimicrobial activity against
periodontal pathogens. In the case of DETA-NO, the remaining amine group would be posi-
tively charged because of protonation in aqueous conditions, and the compound would transi-
tion to a zwitterion form; this form stabilized the NONOates group, resulting in prolonged
release of NO [23]. F68-BPEI is a macromolecule that showed the lowest instantaneous NO
concentration value, with an intermediate duration of release and total amount of NO. The
reason for the longer duration of NO release from F68-BPEI than from Py-NO is similar to
that for DETA-NO.
A. actinomycetemcomitans and P. gingivalis are gram-negative periodontal pathogens that
were susceptible to NO. This finding corresponds to the results of previous studies [9,20]. Py-
NO, which released a higher instantaneous NO concentration with a lower amount of NO,
showed higher MICs and MBCs than DETA-NO, which released a lower instantaneous NO
concentration with a larger amount of NO. These results confirm that the instantaneous NO
concentration was less critical for killing periodontal pathogens than total intracellular NO
delivered over time [9,20]. Furthermore, it has been demonstrated that continuous exposure
of bacteria to gaseous NO is required for an antibacterial effect [24]. Therefore, the duration of
NO release from each compound is a major determinant of antibacterial efficacy.
Bactericidal efficacy depends on surface charge as well as the kinetics of NO release; bacte-
rial cell walls are negatively charged, and positively charged macromolecules can interact with
and disrupt bacterial cell membranes via electrostatic interaction [25]. F68-BPEI had an inhib-
itory effect on periodontal pathogens without NO that may be attributable to the high positive
charge of F68-BPEI itself (20 mV). Compared with Py-NO and DETA-NO, F68-BPEI-NO had
a bactericidal effect with less NO. The factor underlying these results seems to be the total
molecular mass of the NO donor. Previous studies have shown that donors composed of mac-
romolecules have greater NO activity against bacteria than donors composed of mono-mole-
cules [22,26] because of the localization of NO on the macromolecules [22].
We evaluated the bactericidal efficiency of NO against A. israelii, a gram-positive periodon-
tal pathogen and found results similar to those of the bactericidal assays against gram-negative
periodontal pathogens. A. israelii is only one of the strains of bacteria that cause gingivitis;
Actinomyces spp. are also significant pathogens in the etiology of medication-related osteone-
crosis of the jaw (MRONJ) [27,28]. Therefore, the results of this study suggest that NO should
be considered for the treatment of MRONJ. NO may have additional benefits in the treatment
of MRONJ because it promotes angiogenesis [29] and an anti-inflammatory response [30],
and also plays a role in attenuating the adverse effects of bisphosphonates in human gingival
fibroblasts [12].
F68-BPEI becomes strongly positive when secondary amines are attached, causing a non-
specific ionic interaction with negatively charged bacterial membranes and zwitterionic cell
membranes. Therefore, F68-BPEI is highly cytotoxic and also inhibits growth of periodontal
pathogens. Interestingly, in the present study, the cytotoxic effect of F68-BPEI-NO was
improved after addition of NONOates. The positive charge of F68-BPEI (20.88 mV) was
reduced when attached to NONOates, and F68-BPEI-NO had a surface charge that was close
to zero (0.43 mV). NO was added at a relatively low concentration, suggesting that inducing
zero surface charge by addition of NO may have a positive effect on cells. Although a positive
surface charge can improve the bactericidal effect, a lack of surface charge seems to be more
beneficial for the therapeutic use of NO with respect to cytotoxicity. Py-NO was more cyto-
toxic than DETA-NO in our study, which confirms that an instantaneous NO concentration is
more important for increasing cytotoxicity than the total amount of NO released [9,31].
Nitric oxide-releasing compounds for treatment of periodontal disease
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Therefore, a lower instantaneous NO concentration with a greater total amount of NO appears
to have a better bactericidal effect and be less cytotoxic, and a macromolecule may be favorable
as a NO delivery system because of the high efficiency of NO against pathogens.
Eradication of microorganisms from the periodontal pocket is the most important step in
treating periodontitis. The limited effects of mouth rinsing and irrigation have prompted
research on alternative antimicrobial delivery systems. Advances in drug delivery technology
have allowed development of controlled-release drug formulations. The requirements for a
drug delivery system to treat periodontitis include maintenance of an effective drug concentra-
tion for an adequate duration at the site of infection and minimal or no side effects in peri-
odontal tissue [32]. Various devices, including fibers [33], films [34], strips [33,35], gels [36],
and microparticles [37], have been developed for this purpose, and most of the commercially
available injectable and biodegradable carriers have the advantages of being cost-effective, con-
venient to use, and less painful when administered to patients [32]. The antibiotics used in
these carriers include metronidazole, minocycline, chlorhexidine, and tetracycline; however,
patients with chronic periodontitis often have subgingival periodontal pathogens that are resis-
tant to the antibiotics commonly used in clinical periodontal practice [38]. In the present
study, F68-BPEI-NO had an adequate antimicrobial effect against periodontal pathogens and
was minimally cytotoxic to gingival fibroblasts, and can be used in an injectable and biode-
gradable carrier form. Importantly, F68-BPEI-NO could be an effective alternative treatment
for chronic periodontitis caused by pathogens resistant to conventional antibiotics, given our
previous finding that F68-BPEI-NO had a marked bactericidal effect on methicillin-resistant
Staphylococcus aureus [39]. However, release of NO is affected by temperature, which differs
between experimental conditions and the oral cavity. Research in animals is now needed to
confirm the efficacy of NO-releasing compounds in the treatment of periodontal disease.
Additional animal studies are also needed to determine how the amounts of NO-releasing
compounds delivered to the periodontal pockets change over time. The NO-releasing com-
pounds used in this study do not need modification for use in animal studies because they are
biocompatible and injectable. The results of the present study can be used to determine the
concentration of NO-releasing compounds needed in such animal studies.
Conclusion
F68-BPEI-NO may be a prepotent candidate for a topical agent in the treatment of periodontal
disease because it demonstrated sufficient bactericidal effects on periodontal pathogens, with
minimum cytotoxicity to HGF-1 cells. NO donors composed of a macromolecule without sur-
face charge, a lower instantaneous NO concentration, and sufficient total amount of NO had a
strong bactericidal effect and low cytotoxicity.
Supporting information
S1 Fig. Antimicrobial activity of pyrrolidine and DETA against periodontal pathogens. In
comparison to py-NO and DETA-NO, pyrrolidine and DETA showed antimicrobial activity
at a concentration of 10-fold or more, and their antimicrobial effect was attributable to release
of NO.
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